Clinical trials: Erythrocyte Transfusion
Myelodysplastic Syndromes
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
- Trial name
- MAXILUS (NCT06045689)
- Testing
- Luspatercept
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
RPS19 Deficient Diamond-Blackfan Anemia
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia
Brief summary The goal of this clinical trial is to learn if APR-2020 is safe and can help treat Diamond-Blackfan Anemia (DBA) in adolescents and children.
- Trial name
- NCT07476183
- Testing
- APR-2020
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Apriligen, Inc.
Resectable Pancreatic Carcinoma
Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
This clinical trial tests the the feasibility of testing a red blood cell transfusion threshold for improved quality of life for patients undergoing a pancreatectomy for pancreatic cancer.
- Trial name
- NCT05841706
- Testing
- Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Sickle Cell Disease
Age of Blood in Sickle Cell Transfusion
The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads…
- Trial name
- NCT03704922
- Testing
- Transfusion
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
Individualized Transfusion Strategy, Red Blood Cell
Individualized Strategies of Red Blood Cell Transfusion for Perioperative Pediatric Patients
The individualized strategies of red blood cell for perioperative pediatric patients are made based on the comparison between the clinical condition score and the Hb concentration.
- Conditions
- Individualized Transfusion Strategy, Red Blood Cell, Perioperative Pediatric Patient, Clinical Outcome
- Trial name
- NCT04537000
- Testing
- clinical condition score
- Sponsor
- Children's Hospital of Fudan University
Thalassemia Major
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
This study compares the effects of Packed Red Blood Cells (PRBCs) prepared in two different ways on the transfusion indices in beta(ß)-Thalassemia transfusion-dependent patients.
- Trial name
- NCT03992001
- Testing
- Blood component A, Blood component B
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Università degli Studi di Ferrara
G6PD Deficiency
Effect of G6PD Deficiency on Red Blood Cell Storage
The proposed study will determine whether G6PD-deficient RBCs store differently than normal RBCs under standard blood banking conditions.
- Trial name
- NCT04081272
- Testing
- Sodium Chromate Cr51
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Columbia University
Myocardial Injury, Acuter Kidney Injury
Impact of Perioperative Allogeneic Red Blood Cell Transfusion on Postoperative Myocardial Injury After Liver Resection
We aimed to explore the influence of ABT on the incidence of MINS, AKI, and overall prognosis among advanced-age HCC patients who underwent hepatectomy
- Trial name
- NCT07125612
- Volunteers
- 487 people
- Sponsor
- Hao Li
Primary Myelofibrosis, Anemia
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion dependence.
- Trial name
- NCT03194542
- Testing
- Luspatercept
- Where
- 47 sites in United States, France and 2 more
- Volunteers
- 95 people
- Sponsor
- Celgene
Neonatal Anemia
Red Blood Cell (RBC) Survival Following Transfusion in Infants
OUR OVERALL HYPOTHESIS is that post-transfusion survival of allogeneic and autologous RBCs can be accurately quantified in anemic human infants using biotin-labeled RBCs combined with mathematical modeling that adjusts for…
- Trial name
- NCT00731588
- Testing
- Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- John A Widness
Hepatectomy, Transfusion Requirements
Reducing Red Blood Cell Transfusion Requirements for Adults Undergoing Surgical Resection of the Liver - A Quality Improvement Project
The goal of this clinical trial is to determine if implementing a controlled blood removal protocol (i.e. hypovolemic phlebotomy [HP] where approximately 10% of the patient's blood is removed and reinfused following hepatic…
- Conditions
- Hepatectomy, Transfusion Requirements, Intraoperative Bleeding, Intraoperative Monitoring
- Trial name
- NCT07629648
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Dr. Glenio Mizubuti (MD, PhD, FRCPC)
Myelodysplastic Syndromes
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
The purpose of this study is to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk…
- Trial name
- NCT04477850
- Testing
- Luspatercept
- Where
- 25 sites in China, Japan
- Volunteers
- 30 people
- Sponsor
- Celgene
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Sickle Cell Disease, Anti-D Antibodies
RHD Genotype Matched Red Cells for Anti-D
This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are…
- Trial name
- NCT04156906
- Testing
- D+ RH genotype matched red cell units for transfusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital of Philadelphia
Blood Loss Anemia
Small-Volume Tubes to Reduce Anemia and Transfusion
STRATUS will evaluate the use of small-volume ("soft-draw") blood collection tubes for laboratory testing in reducing anemia and transfusion in intensive care unit patients without significant adverse consequences.
- Trial name
- STRATUS (NCT03578419)
- Testing
- Small-Volume Blood Collection Tubes, Standard-Volume Blood Collection Tubes
- Where
- 24 sites in Canada
- Volunteers
- 27,411 people
- Sponsor
- Population Health Research Institute
Cirrhosis
Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock
Consecutive cirrhotics who present to emergency department of ILBS with documented or suspected sepsis induced hypotension with Hb <8 gm/dl will be randomly assigned to restrictive (Target Hb 7-8 gm/dl) to liberal (Target Hb…
- Trial name
- NCT03433508
- Testing
- Liberal, Restrictive
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Sickle Cell Disease, Thalassemia
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and…
- Conditions
- Sickle Cell Disease, Thalassemia, Pediatric Cancer
- Trial name
- RBC-IMPACT (NCT05255445)
- Testing
- Red Blood Cell (RBC) Transfusion
- Where
- 14 sites in United States, Brazil
- Volunteers
- 157 people
- Sponsor
- Westat
Acute Leukemia, Acute Myeloid Leukemia (AML)
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukaemia
- Trial name
- BAIT (NCT06947044)
- Testing
- RBC transfusion strategy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Donald Arnold
Red Blood Cell Transfusion
The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a…
- Trial name
- TheRAPy (NCT06230198)
- Testing
- retrograde autologous priming (RAP), Crystalloid priming
- Where
- 4 sites in Canada
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Population Health Research Institute
Infant, Newborn, Infant, Low Birth Weight
The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants
This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of <1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would…
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- EPO (NCT01203514)
- Testing
- Erythropoietin
- Where
- 9 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network